CCXI Stock Rockets; Amgen Plans $3.7 Billion ChemoCentryx Buyout As Generics Loom | Investor's Business Daily - Investor's Business Daily

The company will pay $52 per share to buy ChemoCentryx, a rare disease-focused firm.

Amgen (AMGN) agreed to buy ChemoCentryx (CCXI) for $3.7 billion on Thursday, leading CCXI stock to rocket. XChemoCentryx is focused on rare and orphan diseases, particularly those in the autoimmune,… [+3034 chars]

full article...